4
Changes in Ownership
Celldex Therapeutics, Inc. Filed Acc 0001415889-22-012301
EXECUTIVE VP & CSO sold 16,860 shares at $36.93 ($622,611)
- EXECUTIVE VP & CSO acquired 16,860 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| KELER TIBOR EXECUTIVE VP & CSO | 2022-12-07 | Option exercise | +16,860 | $2.78 | $46,871 | 24,217 | D |
| KELER TIBOR EXECUTIVE VP & CSO | 2022-12-07 | Sale | −16,860 | $36.93 | $622,611 | 7,357 | D |
| Derivatives | |||||||
| KELER TIBOR EXECUTIVE VP & CSO | 2022-12-07 | Option exercise · Incentive Stock Option (right to buy) | −16,860 | 43,140 | D | ||
| Open-market sales · 16,860 sh · avg $36.93 · $622,611 | |||||||
Loading xslF345X03/form4-12092022_091203.xml…